Ventritex
This article was originally published in The Gray Sheet
Executive Summary
Begins distribution of its Cadence V-110 implantable cardioverter-defibrillator following Aug. 8 approval of the PR 1500 Cadence Programmer. The V-110 was approved via a PMA supplement in June, but full release of the device was dependent upon approval of the Cadence Programmer. The biphasic, tiered- therapy defibrillator weighs 15% less than the current Cadence V- 100, and is priced at $18,900